Spyre Therapeutics (SYRE) Interest Expenses (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Interest Expenses came in at $1.1 million in Q1 2026, up 556.52% YoY from $161000.0 in Q1 2025, and up 811.21% on a QoQ basis from $116000.0 in Q4 2025.
Spyre Therapeutics (SYRE) Interest Expenses (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Interest Expenses data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Interest Expenses rose 556.52% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 556.52% YoY) and the FY2025 annual result came in at $201.3 million, up 23.58% from the prior year.
- Interest Expenses rose to $1.1 million in Q1 2026, from $116000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $162.9 million in Q4 2024 to a low of $20000.0 in Q3 2024.
- A 5-year average of $19.5 million and a median of $161000.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 65947.89% — and 2025, when it tumbled 99.93%.
- Tracing SYRE's Interest Expenses over 5 years: stood at $190000.0 in 2022, then soared by 65947.89% to $125.5 million in 2023, then grew by 29.83% to $162.9 million in 2024, then plunged by 99.93% to $116000.0 in 2025, then soared by 811.21% to $1.1 million in 2026.
- The last three Interest Expenses figures came in at $1.1 million (Q1 2026), $116000.0 (Q4 2025), and $38000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.49 Mn |
| Jun 30, 2026 | 2.49 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 116,000.00 |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 162.93 Mn |
| Dec 31, 2024 | 162.93 Mn |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 673,000.00 |
| Jun 30, 2024 | 673,000.00 |
| Mar 31, 2024 | 451,000.00 |
| Mar 31, 2024 | 451,000.00 |